• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Targeted small molecule therapy and inhibitors for lymphoma.淋巴瘤的靶向小分子治疗药物和抑制剂。
Future Med Chem. 2024;16(14):1465-1484. doi: 10.1080/17568919.2024.2359893. Epub 2024 Jul 17.
2
Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.布鲁顿酪氨酸激酶抑制剂治疗难治性或复发性原发性中枢神经系统淋巴瘤：一项荟萃分析和系统评价。
World Neurosurg. 2024 Aug;188:161-169. doi: 10.1016/j.wneu.2024.04.066. Epub 2024 Apr 17.
3
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas.发现新型 BTK 抑制剂 S-016 并确定治疗包括 BTK 抑制剂耐药淋巴瘤在内的淋巴瘤的新策略。
Acta Pharmacol Sin. 2024 Oct;45(10):2163-2173. doi: 10.1038/s41401-024-01311-x. Epub 2024 Jun 4.
4
Design, synthesis, and biological evaluation of N-(2-amino-phenyl)-5-(4-aryl- pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment.N-(2-氨基苯基)-5-(4-芳基嘧啶-2-基氨基)-1H-吲哚-2-甲酰胺衍生物作为新型CDK9和I类组蛋白去乙酰化酶抑制剂用于癌症治疗的设计、合成及生物学评价
Bioorg Chem. 2025 Jul 15;162:108577. doi: 10.1016/j.bioorg.2025.108577. Epub 2025 May 10.
5
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.伏立诺他是一种组蛋白去乙酰化酶（HDAC）抑制剂，可促进细胞周期停滞，并使利妥昔单抗和化疗耐药的淋巴瘤细胞对化疗药物重新敏感。
J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28.
6
Evaluating remibrutinib in the treatment of chronic spontaneous urticaria.评估瑞比鲁替尼治疗慢性自发性荨麻疹的效果。
Immunotherapy. 2025 May;17(7):479-484. doi: 10.1080/1750743X.2025.2510892. Epub 2025 Jun 2.
7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
High-Risk Neuroblastoma Stage 4 (NBS4): Developing a Medicinal Chemistry Multi-Target Drug Approach.高危神经母细胞瘤4期（NBS4）：开发一种药物化学多靶点药物方法。
Molecules. 2025 May 19;30(10):2211. doi: 10.3390/molecules30102211.

本文引用的文献

1
Anticancer clinical efficiency and stochastic mechanisms of belinostat.贝林司他的抗癌临床疗效和随机机制。
Biomed Pharmacother. 2023 Sep;165:115212. doi: 10.1016/j.biopha.2023.115212. Epub 2023 Aug 2.
2
Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.在复发/难治性 T 细胞淋巴瘤患者中，tenalisib 联合 romidepsin 的安全性和有效性：一项 I/II 期开放标签多中心研究的结果。
Haematologica. 2024 Jan 1;109(1):209-219. doi: 10.3324/haematol.2022.281875.
3
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.ELEVATE-RR 试验中，阿卡替尼与伊布替尼治疗复发/难治性慢性淋巴细胞白血病的详细安全性比较。
Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818.
4
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.依地鲁赛布治疗慢性淋巴细胞白血病患者——来自德国慢性淋巴细胞白血病研究组注册登记处的真实世界数据。
Ann Hematol. 2023 Nov;102(11):3083-3090. doi: 10.1007/s00277-023-05314-2. Epub 2023 Jun 26.
5
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.帕博利珠单抗联合伏立诺他可诱导既往 PD-1 阻断治疗耐药的霍奇金淋巴瘤患者应答。
Blood. 2023 Oct 19;142(16):1359-1370. doi: 10.1182/blood.2023020485.
6
Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin.罗米地辛抗癌治疗效果的分子机制途径。
Biomed Pharmacother. 2023 Aug;164:114774. doi: 10.1016/j.biopha.2023.114774. Epub 2023 May 22.
7
Differential Response of Mycosis Fungoides Cells to Vorinostat.蕈样肉芽肿细胞对伏立诺他的差异化反应。
Int J Mol Sci. 2023 Apr 29;24(9):8075. doi: 10.3390/ijms24098075.
8
Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders.派利替尼：BTK 抑制剂难治性淋巴增生性疾病患者的新希望。
Blood. 2023 Jun 29;141(26):3137-3142. doi: 10.1182/blood.2023020240.
9
Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma.泽布替尼治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤比伊布替尼更有效且耐受性更好。
Cancer. 2023 May 15;129(10):1466. doi: 10.1002/cncr.34811.
10
Synthesis and evaluation of sulfonamide derivatives targeting EGFR mutations and ALK rearrangement as anticancer agents.合成及评价针对 EGFR 突变和 ALK 重排的磺胺衍生物作为抗癌剂。
Bioorg Med Chem. 2023 May 1;85:117241. doi: 10.1016/j.bmc.2023.117241. Epub 2023 Mar 17.

淋巴瘤的靶向小分子治疗药物和抑制剂。

Targeted small molecule therapy and inhibitors for lymphoma.

机构信息

College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, P. R. China.

Core Facility,The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou 324000, P. R. China.

出版信息

Future Med Chem. 2024;16(14):1465-1484. doi: 10.1080/17568919.2024.2359893. Epub 2024 Jul 17.

DOI:10.1080/17568919.2024.2359893
PMID:39016063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11352716/
Abstract

Lymphoma, a blood tumor, has become the ninth most common cancer in the world in 2020. Targeted inhibition is one of the important treatments for lymphoma. At present, there are many kinds of targeted drugs for the treatment of lymphoma. Studies have shown that Histone deacetylase, Bruton's tyrosine kinase and phosphoinositide 3-kinase all play an important role in the occurrence and development of tumors and become important and promising inhibitory targets. This article mainly expounds the important role of these target protein in tumors, and introduces the mechanism of action, structure-activity relationship and clinical research of listed small molecule inhibitors of these targets, hoping to provide new ideas for the treatment of lymphoma.

摘要

淋巴瘤是一种血液肿瘤，已成为 2020 年全球第九大常见癌症。靶向抑制是淋巴瘤的重要治疗方法之一。目前，针对淋巴瘤的治疗有多种靶向药物。研究表明，组蛋白去乙酰化酶、布鲁顿酪氨酸激酶和磷酸肌醇 3-激酶在肿瘤的发生和发展中都起着重要作用，成为重要且有前途的抑制靶点。本文主要阐述了这些靶蛋白在肿瘤中的重要作用，并介绍了这些靶点的已上市小分子抑制剂的作用机制、构效关系和临床研究，希望为淋巴瘤的治疗提供新的思路。